AUS
NZ
UK
CA
USA
IND
Highlights
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) receives patent grant in China for RECCE 327 and RECCE 529
Patent strengthens global protection covering use, administration, and manufacturing methods
Company progresses with trials across Southeast Asia and the US, focusing on bacterial and viral infections
Recce Pharmaceuticals Ltd (ASX:RCE), (OTC:RECEF), a biotechnology company operating within the healthcare and pharmaceutical sector, has advanced its intellectual property portfolio with a newly granted patent in China. This patent includes RECCE 327 and RECCE 529, synthetic anti-infective compounds designed for bacterial and viral infections, respectively. The patent reinforces the company’s innovation strategy and regulatory footprint across major healthcare markets, enhancing its standing among ASX 200 constituents.
The new patent spans key aspects of treatment including methods of use, routes of administration, and manufacturing techniques. It is set to extend coverage in the Chinese market, aligning with regulatory frameworks and commercialisation pathways across Asia’s expanding healthcare landscape.
Expanded Protection for Anti-Infective Candidates
RECCE 327, aimed at bacterial infections, and RECCE 529, focused on viral diseases, now benefit from extended intellectual property rights in China. The protection granted supports therapeutic claims across a wide spectrum of medical conditions such as acute bacterial skin and skin structure infections, diabetic foot ulcers, urinary tract infections, gonorrhoea, and pneumonia.
The patent scope includes various elements of product application and formulation, which enables Recce Pharmaceuticals Ltd (ASX:RCE) to strengthen its position in both treatment development and future regulatory processes. This milestone also supports the company's ability to address unmet needs in both community and hospital-based healthcare settings.
Clinical Developments Across Asia and the US
Recce Pharmaceuticals Ltd (ASX:RCE) is currently conducting a late-stage clinical trial in Indonesia focused on bacterial complications linked to diabetic foot ulcers. The trial is part of a broader strategy to expand access in Southeast Asia, where collaborative regulatory initiatives between nations may enable broader approvals following successful outcomes.
Interim data from the Indonesian study is expected in the near term, and Recce has noted that these developments may align with strategic goals to reach other markets in the ASEAN region.
In the United States, the company is preparing to initiate a Phase III trial centered on acute bacterial infections, based on data from earlier studies completed in Australia. These trials reflect the global scale of Recce’s clinical pipeline, supporting its research-driven approach to addressing infectious diseases.
Patent Reinforces International Presence
The intellectual property enhancement in China marks a significant expansion in Recce Pharmaceuticals’ (ASX:RCE, OTC:RECEF) global strategy. The extended protection timeframe provides legal and regulatory support for ongoing development and partnerships in one of the world’s largest pharmaceutical markets.
By securing rights across multiple therapeutic categories and delivery methods, Recce aims to maintain its trajectory in the synthetic anti-infective segment. The strategic alignment with large-scale health markets reflects broader developments within the biotechnology industry and supports global ambitions for market presence.
This latest patent complements existing protections in other regions and contributes to the evolving commercial strategy of Recce Pharmaceuticals Ltd as it progresses with ongoing trials and future product applications.
